Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 2.6%, while the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 2.4% [1] - The China Securities Innovative Drug Industry Index and the China Securities Biotechnology Theme Index saw increases of 1.4% and 1.0% respectively, with the CSI 300 Pharmaceutical and Health Index rising by 0.9% [1] - Huachuang Securities stated that the fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the continuous demand for pharmaceuticals and the increasing number of unmet needs, along with pharmaceutical companies' ongoing investment in R&D to meet these demands [1] - China has become a significant player in global innovative drug R&D, with overseas licensing activity continuing to rise year after year, marking the pharmaceutical industry’s entry into a revenue era driven by innovation [1]
医药板块集体走强，港股通创新药ETF易方达（159316）、港股通医药ETF易方达（513200）标的指数涨超2%
Mei Ri Jing Ji Xin Wen·2026-02-10 13:47